Clinical trial · Interventional
4D Image-guided Adaptive Radiotherapy for Lung Cancer: Patient Image Acquisition
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial studies 4-dimensional (4-D) image-guided radiation therapy treatment planning in patients with stage I-IV non-small cell lung cancer. Computed tomography (CT) scans and treatment-planning systems may help in planning radiation therapy for patients with non-small cell lung cancer. This is not a therapy study. Therefore no direct benefit from participating is expected. However, at the discretion of the treating physician, the information gained from the additional imaging will be used to improve treatment accuracy. No patient outcome data are gathered or analyzed by this study. This study is not a:Phase I, II, or III trial, trial with "blinded" treatment arm, gene or a vaccine trial, or a multi-institutional trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 4-dimensional computed tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CT Imaging
- description
- Patients undergo 4-D, 4-dimensional computed tomography, CT imaging prior to radiotherapy sessions and once a week at the end of treatment.
- interventionNames
- Procedure: 4-dimensional computed tomography
Primary outcomes (3)
- measure
- At least 1 mm reduction in overall systematic error corresponding with ≥ 2 mm CTV-PTV margin reduction
- timeFrame
- Up to 7 years
- measure
- At least 5 Gy reduction in mean lung dose
- timeFrame
- up to 7 years
- measure
- At least 5% reduction in absolute pneumonitis risk (≥ grade 2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic or cytologic confirmation of non-small cell lung cancer stages I-IV * Partial pressure oxygen (pO2) \> 92%-obtained at the time of or within 3 months prior to initial consultation with the radiation oncologist * Tumor(s) must be visualized on a CT * Positron emission tomography (PET) is performed during staging or treatment planning process * All patients must be informed on the investigational nature of this study and must give informed consent in accordance with institutional guidelines Exclusion Criteria: * Pregnant women may not participate; women of reproductive potential must be informed of the need to practice an effective contraceptive method * Unstable coronary artery disease * Uncorrectable coagulopathy * Severe pulmonary hypertension * Poor tolerance of conscious sedation
References
Publications (0)
Data not yet available